Directors' Dealings

31 Aug 2007 13:27

Omega Diagnostics Group PLC31 August 2007 Omega Diagnostics Group PLC 31 August 2007 Omega Diagnostics Group PLC ("Omega" or "the Company") Directors Shareholdings & Issue of Equity Omega Diagnostics Group PLC announces that following its share consolidation andcapital reorganization (the "Share Consolidation" and the "CapitalReorganisation" respectively), 9,684,470 new Ordinary Shares of 4 pence each ("New Ordinary Shares") have today been admitted to AIM (the "First Admission").Application has been made for a further 5,191,223 New Ordinary Shares to beadmitted to AIM, which is expected to become effective on 3 September 2007 (the"Second Admission"). As part of the placing related to the acquisitions of Genesis DiagnosticsLimited and Cambridge Nutritional Sciences Limited announced on 6 August 2007and approved by shareholders at the EGM of the Company yesterday (the "Placing"), David Evans, Non-Executive Chairman and Andrew Shepherd, Chief Executive Officer of the Company have today purchased New Ordinary Shares at the placing price of 30p per share. The number of New Ordinary Shares purchased by each Director and their resultant holding of New Ordinary Shares in the Company is set out below: No. of New Interest in New Interest in total Interest in total Ordinary Shares Ordinary Shares issued share issued share purchased as part following the capital following capital following of the Placing Placing First Admission Second Admission David Evans, Non-Executive 100,000 100,000 1.03% 0.67%Chairman Andrew Shepherd, Chief 100,000 902,568 9.32% 6.07%Executive Officer In addition, in accordance with the details of the Share Consolidation set outin the Admission Document published on 3 August 2007, David Evans yesterdaypurchased 25 non-consolidated Ordinary Shares of 1p each in the Company ("OldOrdinary Shares") at the price of 1p per Old Ordinary Share, being the par valueof the Old Ordinary Shares. This was in order to increase the issued sharecapital of the Company to a number divisible by 40 prior to the ShareConsolidation becoming effective. Following this transaction, David Evans heldless than 0.01% of yesterday's issued share capital. Following the implementation of the Share Consolidation, these 25 Old OrdinaryShares are now a fraction of a New Ordinary Share and have been aggregated withthe fractions of New Ordinary Shares to which other fractional shareholders ofthe Company are entitled so as to form full New Ordinary Shares and will be soldin the market for the benefit of the Company. In total there are 19 NewOrdinary Shares resulting from fractional entitlements to New Ordinary Shares. The issue of 25 Old Ordinary Shares of 1p each to David Evans has resulted inone additional New Ordinary Share following aggregation with other fractionalentitlements after the Share Consolidation. Application has been made for thisadditional New Ordinary Share to be admitted to trading on AIM, which isexpected to become effective on 6 September 2007. Following Admission of thisadditional New Ordinary Share the Company's issued share capital will consist of14,875,694 New Ordinary Shares. Contacts: Omega Diagnostics Group PLCTel: 01259 763030 Andrew Shepherd, Chief ExecutiveKieron Harbinson, Finance Directorwww.omegadiagnostics.com Landsbanki Securities (UK) LimitedNominated Adviser & BrokerTel: 020 7426 9000 Thilo Hoffmann/Simon Brown, Corporate Finance Parkgreen Communications LimitedBen KnowlesT. 020 7479 7933Mob. 07900 346 978Ben.knowles@parkgreenmedia.com This information is provided by RNS The company news service from the London Stock Exchange